Biomarkers for Hepatocellular Apoptosis in the Management of Liver Diseases

Current Pharmaceutical Biotechnology

Volumn 13, Issue 11, 2012, Pages 2221-2227

  St Pierre, Marie V ^a   Dufour, Jean François ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cytokeratin 18; Fas antigen; Fas ligand; Soluble trail; Tumour necrosis factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BIOLOGICAL MARKER; CYTOKERATIN 18; FAS ANTIGEN; FAS LIGAND; INTERFERON; PARACETAMOL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LIVER FAILURE; APOPTOSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER DISEASE; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PATHOLOGY; REVIEW; VIRUS HEPATITIS; VIRUS LOAD;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; HEPATOCYTES; HUMANS; LIVER DISEASES;

EID: 84873454297     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112802502097     Document Type: Review

References (69)

1. Ashkenazi, A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat. Rev. Cancer, 2002, 2, 420-430.
2. Guicciardi, M. E.; Gores, G. J. Apoptosis as a mechanism for liver disease progression. Semin. Liver Dis., 2010, 30, 402-410.
3. Zender, L.; Hutker, S.; Liedtke, C.; Tillmann, H. L.; Zender, S.; Mundt, B.; Waltemathe, M.; Gosling, T.; Flemming, P.; Malek, N. P.; Trautwein, C.; Manns, M. P.; Kuhnel, F.; Kubicka, S. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc. Natl. Acad. Sci. USA, 2003, 100, 7797-802.
4. Yin, X. M.; Wang, K.; Gross, A.; Zhao, Y.; Zinkel, S.; Klocke, B.; Roth, K. A.; Korsmeyer, S. J. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature, 1999, 400, 886-891.
5. Liu, H.; Lo, C. R.; Czaja, M. J. NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology, 2002, 35, 772-778.
6. Guicciardi, M. E.; Leist, M.; Gores, G. J. Lysosomes in cell death. Oncogene, 2004, 23, 2881-2890.
7. Saelens, X.; Festjens, N.; Vande Walle, L.; van Gurp, M.; van Loo, G.; Vandenabeele, P. Toxic proteins released from mitochondria in cell death. Oncogene, 2004, 23, 2861-2874.
8. Jost, P. J.; Grabow, S.; Gray, D.; McKenzie, M. D.; Nachbur, U.; Huang, D. C.; Bouillet, P.; Thomas, H. E.; Borner, C.; Silke, J.; Strasser, A.; Kaufmann, T. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature, 2009, 460, 1035-1039.
9. Scaffidi, C.; Fulda, S.; Srinivasan, A.; Friesen, C.; Li, F.; Tomaselli, K. J.; Debatin, K. M.; Krammer, P. H.; Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways, EMBO J., 1998, 17, 1675-1687.
10. Zhan, S. S.; Jiang, J. X.; Wu, J.; Halsted, C.; Friedman, S. L.; Zern, M. A.; Torok, N. J. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo, Hepatology, 2006, 43, 435-443.
11. Oksuz, M.; Akkiz, H.; Isiksal, Y. F.; Saydaogluc, G.; Serin, M.; Kayaselcuk, F.; Abayli, B.; Tuncer, I. Expression of Fas antigen in liver tissue of patients with chronic hepatitis B and C. Eur. J. Gastroenterol. Hepatol., 2004, 16, 341-345.
12. Bantel, H.; Lugering, A.; Poremba, C.; Lugering, N.; Held, J.; Domschke, W.; Schulze-Osthoff, K. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology, 2001, 34, 758-767.
13. Pianko, S.; Patella, S.; Ostapowicz, G.; Desmond, P.; Sievert, W. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J. Viral Hepatol., 2001, 8, 406-413.
14. Tagami, A.; Ohnishi, H.; Moriwaki, H.; Phillips, M.; Hughes, R. D. Fas-mediated apoptosis in acute alcoholic hepatitis. Hepatogastroenterology, 2003, 50, 443-448.
15. Malhi, H.; Bronk, S. F.; Werneburg, N. W.; Gores, G. J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem., 2006, 281, 12093-12101.
16. Gunawan, B. K.; Liu, Z. X.; Han, D.; Hanawa, N.; Gaarde, W. A.; Kaplowitz, N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology, 2006, 131, 165-178.
17. Henderson, N. C.; Pollock, K. J.; Frew, J.; Mackinnon, A. C.; Flavell, R. A.; Davis, R. J.; Sethi, T.; Simpson, K. J. Critical role of cjun (NH2) terminal kinase in paracetamol-induced acute liver failure. Gut, 2007, 56, 982-990.
18. Rudiger, H. A.; Graf, R.; Clavien, P. A. Liver ischemia: apoptosis as a central mechanism of injury. J. Invest. Surg., 2003, 16, 149-159.
19. Gao, W.; Bentley, R. C.; Madden, J. F.; Clavien, P. A. Apoptosis of sinusoidal endothelial cells is a critical mechanism of preservation injury in rat liver transplantation. Hepatology, 1998, 27, 1652-1660.
20. Roth, G. A.; Krenn, C.; Brunner, M.; Moser, B.; Ploder, M.; Spittler, A.; Pelinka, L.; Sautner, T.; Wolner, E.; Boltz-Nitulescu, G.; Ankersmit, H. J. Elevated serum levels of epithelial cell apoptosisspecific cytokeratin 18 neoepitope m30 in critically ill patients. Shock, 2004, 22, 218-220.
21. Kramer, G.; Erdal, H.; Mertens, H. J.; Nap, M.; Mauermann, J.; Steiner, G.; Marberger, M.; Biven, K.; Shoshan, M. C.; Linder, S. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res., 2004, 64, 1751-1756.
22. Kronenberger, B.; Zeuzem, S.; Sarrazin, C.; Mihm, U.; von Wagner, M.; Hofmann, W. P.; Piiper, A.; Herrmann, E. Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C. Antivir. Ther., 2007, 12, 779-787.
23. Bantel, H.; Lugering, A.; Heidemann, J.; Volkmann, X.; Poremba, C.; Strassburg, C. P.; Manns, M. P.; Schulze-Osthoff, K. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology, 2004, 40, 1078-1087.
24. Zeuzem, S.; Schmidt, J. M.; Lee, J. H.; Ruster, B.; Roth, W. K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology, 1996, 23, 366-371.
25. Marcellin, P.; Asselah, T.; Boyer, N. Fibrosis and disease progression in hepatitis C. Hepatology, 2002, 36, S47-56.
26. Sgier, C.; Mullhaupt, B.; Gerlach, T.; Moradpour, D.; Negro, F.; Male, P. J.; Heim, M. H.; Malinverni, R.; Cerny, A.; Dufour, J. F. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. J. Viral Hepatol., 2010.
27. Kronenberger, B.; Wagner, M.; Herrmann, E.; Mihm, U.; Piiper, A.; Sarrazin, C.; Zeuzem, S. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J. Viral Hepatol., 2005, 12, 307-314.
28. Papatheodoridis, G. V.; Hadziyannis, E.; Tsochatzis, E.; Georgiou, A.; Kafiri, G.; Tiniakos, D. G.; Margariti, K.; Manolakopoulos, S.; Manesis, E. K.; Archimandritis, A. J. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. J. Clin. Gastroenterol., 2010, 44, e87-95.
29. Papatheodoridis, G. V.; Hadziyannis, E.; Tsochatzis, E.; Chrysanthos, N.; Georgiou, A.; Kafiri, G.; Manolakopoulos, S.; Tiniakos, D. G.; Giannousis, I.; Manesis, E. K.; Archimandritis, A. J. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection, Gut, 2008, 57, 500-506.
30. Eren, F.; Yilmaz, Y.; Kose, S.; Ozdemir, F. T.; Yonal, O.; Kurt, R.; Ozdogan, O.; Avsar, E. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clin. Chim. Acta, 411, 2029-2032.
31. Hetz, H.; Hoetzenecker, K.; Hacker, S.; Faybik, P.; Pollreisz, A.; Moser, B.; Roth, G.; Hoetzenecker, W.; Lichtenauer, M.; Klinger, M.; Krenn, C. G.; Ankersmit, H. J. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. J. Clin. Lab. Anal., 2007, 21, 277-281.
32. Rutherford, A. E.; Hynan, L. S.; Borges, C. B.; Forcione, D. G.; Blackard, J. T.; Lin, W.; Gorman, A. R.; Shaikh, O. S.; Reuben, A.; Harrison, E.; Reddy, K. R.; Le, W. M.; Chung, R. T. Serum apoptosis markers in acute liver failure: a pilot study. Clin. Gastroenterol. Hepatol., 2007, 5, 1477-1483.
33. Hofer, S.; Brenner, T.; Bopp, C.; Steppan, J.; Lichtenstern, C.; Weitz, J.; Bruckner, T.; Martin, E.; Hoffmann, U.; Weigand, M. A. Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction. Crit. Care, 2009, 13, R93.
34. Feldstein, A.; Kleiner, D.; Kravetz, D.; Buck, M. Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor. J. Clin. Gastroenterol., 2009, 43, 374-381.
35. Canbakan, B.; Senturk, H.; Canbakan, M.; Toptas, T.; Tabak, O.; Balci, H.; Olgac, V.; Ozbay, G. Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease?, Biomark Med., 2010, 4, 205-214.
36. Wieckowska, A.; Zein, N. N.; Yerian, L. M.; Lopez, A. R.; McCullough, A. J.; Feldstein, A. E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology, 2006, 44, 27-33.
37. Vos, M. B.; Barve, S.; Joshi-Barve, S.; Carew, J. D.; Whitington, P. F.; McClain, C. J. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr., 2008, 47, 481-485.
38. Malik, R.; Chang, M.; Bhaskar, K.; Nasser, I.; Curry, M.; Schuppan, D.; Byrnes, V.; Afdhal, N. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol., 2009, 24, 564-568.
39. Tsutsui, M.; Tanaka, N.; Kawakubo, M.; Sheena, Y.; Horiuchi, A.; Komatsu, M.; Nagaya, T.; Joshita, S.; Umemura, T.; Ichijo, T.; Matsumoto, A.; Yoshizawa, K.; Aoyama, T.; Tanaka, E.; Sano, K. Serum Fragmented Cytokeratin 18 Levels Reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J. Clin. Gastroenterol., 2010, 44(6),440-447.
40. Yilmaz, Y.; Dolar, E.; Ulukaya, E.; Akgoz, S.; Keskin, M.; Kiyici, M.; Yerci, O.; Oral, A. Y.; Gul, C. B.; Gurel, S.; Nak, S. G.; Gulten, M. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. Med. Sci. Monit., 2009, 15, CR189-193.
41. Younossi, Z. M.; Page, S.; Rafiq, N.; Birerdinc, A.; Stepanova, M.; Hossain, N.; Afendy, A.; Younoszai, Z.; Goodman, Z.; Baranova, A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg, 2010, 21(4),431-439.
42. Balmer, M. L.; Siegrist, K.; Zimmermann, A.; Dufour, J. F. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver Int., 2009, 29(8),1184-1188
43. Civera, M.; Urios, A.; Garcia-Torres, M. L.; Ortega, J.; Martinez-Valls, J.; Cassinello, N.; del Olmo, J. A.; Ferrandez, A.; Rodrigo, J. M.; Montoliu, C. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab. Res. Rev., 2010, 26, 187-192.
44. Tan, S.; Bechmann, L. P.; Benson, S.; Dietz, T.; Eichner, S.; Hahn, S.; Janssen, O. E.; Lahner, H.; Gerken, G.; Mann, K.; Canbay, A. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2010, 95, 343-348.
45. Malhi, H.; Guicciardi, M. E.; Gores, G. J. Hepatocyte death: a clear and present danger. Physiol. Rev., 2010, 90, 1165-1194.
46. Cascino, I.; Fiucci, G.; Papoff, G.; Ruberti, G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 1995, 154, 2706-2713.
47. Iio, S.; Hayashi, N.; Mita, E.; Ueda, K.; Mochizuki, K.; Hiramatsu, N.; Kanto, T.; Sasaki, Y.; Kasahara, A.; Hori, M. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J. Hepatol., 1998, 29, 517-523.
48. Hiramatsu, N.; Hayashi, N.; Katayama, K.; Mochizuki, K.; Kawanishi, Y.; Kasahara, A.; Fusamoto, H.; Kamada, T. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology, 1994, 19, 1354-1359.
49. Mochizuki, K.; Hayashi, N.; Hiramatsu, N.; Katayama, K.; Kawanishi, Y.; Kasahara, A.; Fusamoto, H.; Kamada, T. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J. Hepatol., 1996, 24, 1-7.
50. Ozaslan, E.; Kilicarslan, A.; Simsek, H.; Tatar, G.; Kirazli, S. Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease. J. Int. Med. Res., 2003, 31, 384-391.
51. Ohkawa, K.; Hiramatsu, N.; Mochizuki, K.; Mita, E.; Iio, S.; Yoshihara, H.; Kato, M.; Masuzawa, M.; Kasahara, A.; Sasaki, Y.; Hori, M.; Hayashi, N. Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response. J. Gastroenterol. Hepatol., 2001, 16, 1009-1014.
52. Toyoda, M.; Kakizaki, S.; Horiguchi, N.; Sato, K.; Takayama, H.; Takagi, H.; Nagamine, T.; Mori, M. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferonalpha therapy in chronic hepatitis C. Liver, 2000, 20, 305-311.
53. Kakiuchi, Y.; Yuki, N.; Iyoda, K.; Sugiyasu, Y.; Kaneko, A.; Kato, M. Circulating soluble Fas levels in patients with hepatitis C virus infection and interferon therapy. J. Gastroenterol., 2004, 39, 1189-1195.
54. Lapinski, T. W.; Kowalczuk, O.; Prokopowicz, D.; Chyczewski, L. Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients. World J. Gastroenterol., 2004, 10, 3650-3653.
55. Raghuraman, S.; Abraham, P.; Daniel, H. D.; Ramakrishna, B. S.; Sridharan, G. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection. J. Clin. Virol., 2005, 34, 63-70.
56. Ito, Y.; Monden, M.; Takeda, T.; Eguchi, H.; Umeshita, K.; Nagano, H.; Nakamori, S.; Dono, K.; Sakon, M.; Nakamura, M.; Tsujimoto, M.; Nakahara, M.; Nakao, K.; Yokosaki, Y.; Matsuura, N. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br. J. Cancer, 2000, 82, 1211-1217.
57. Jodo, S.; Kobayashi, S.; Nakajima, Y.; Matsunaga, T.; Nakayama, N.; Ogura, N.; Kayagaki, N.; Okumura, K.; Koike, T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin. Exp. Immunol., 1998, 112, 166-171.
58. Ryo, K.; Kamogawa, Y.; Ikeda, I.; Yamauchi, K.; Yonehara, S.; Nagata, S.; Hayashi, N. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am. J. Gastroenterol., 2000, 95, 2047-2055.
59. Nakae, H.; Narita, K.; Endo, S. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure. J. Crit. Care, 2001, 16, 59-63.
60. Singhal, S.; Chakravarty, A.; Das, B. C.; Kar, P. Tumour necrosis factor-alpha and soluble Fas ligand as biomarkers in nonacetaminophen-induced acute liver failure. Biomarkers, 2009, 14, 347-353.
61. Tagami, A.; Ohnishi, H.; Hughes, R. D. Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose. Hepatogastroenterology, 2003, 50, 742-745.
62. Tokushige, K.; Yamaguchi, N.; Ikeda, I.; Hashimoto, E.; Yamauchi, K.; Hayashi, N. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am. J. Gastroenterol., 2000, 95, 2040-2046.
63. Pelli, N.; Floreani, A.; Torre, F.; Delfino, A.; Baragiotta, A.; Contini, P.; Basso, M.; Picciotto, A. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Clin. Exp. Immunol., 2007, 148, 85-89.
64. Taieb, J.; Mathurin, P.; Poynard, T.; Gougerot-Pocidalo, M. A.; Chollet-Martin, S. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet, 1998, 351, 1930-1931.
65. Zheng, S. J.; Wang, P.; Tsabary, G.; Chen, Y. H. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest., 2004, 113, 58-64.
66. Pelli, N.; Torre, F.; Delfino, A.; Basso, M.; Picciotto, A. Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C. J. Interferon. Cytokine Res., 2006, 26, 119-123.
67. Liang, Y.; Yang, Z.; Li, C.; Zhu, Y.; Zhang, L.; Zhong, R. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin. Exp. Med., 2008, 8, 1-7.
68. Canbay, A.; Feldstein, A.; Baskin-Bey, E.; Bronk, S. F.; Gores, G. J. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J. Pharmacol. Exp. Ther., 2004, 308, 1191-1196.
69. Pockros, P. J.; Schiff, E. R.; Shiffman, M. L.; McHutchison, J. G.; Gish, R. G.; Afdhal, N. H.; Makhviladze, M.; Huyghe, M.; Hecht, D.; Oltersdorf, T.; Shapiro, D. A. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology, 2007, 46, 324-329.